
    
      This proof of concept study will evaluate the effect of roflumilast and pioglitazone on
      transaminase levels and liver fat content.

      Takeda has chosen not to continue this Study, however, randomized subjects were allowed to
      complete the study per protocol.

      The decision to terminate the study is not related to any safety concerns with either of the
      study medications.
    
  